全文获取类型
收费全文 | 4865篇 |
免费 | 297篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 147篇 |
妇产科学 | 111篇 |
基础医学 | 877篇 |
口腔科学 | 140篇 |
临床医学 | 431篇 |
内科学 | 955篇 |
皮肤病学 | 163篇 |
神经病学 | 675篇 |
特种医学 | 197篇 |
外科学 | 466篇 |
综合类 | 26篇 |
一般理论 | 2篇 |
预防医学 | 249篇 |
眼科学 | 68篇 |
药学 | 323篇 |
中国医学 | 2篇 |
肿瘤学 | 285篇 |
出版年
2023年 | 38篇 |
2022年 | 56篇 |
2021年 | 105篇 |
2020年 | 83篇 |
2019年 | 120篇 |
2018年 | 109篇 |
2017年 | 81篇 |
2016年 | 128篇 |
2015年 | 156篇 |
2014年 | 171篇 |
2013年 | 186篇 |
2012年 | 345篇 |
2011年 | 368篇 |
2010年 | 215篇 |
2009年 | 206篇 |
2008年 | 348篇 |
2007年 | 326篇 |
2006年 | 310篇 |
2005年 | 287篇 |
2004年 | 303篇 |
2003年 | 288篇 |
2002年 | 251篇 |
2001年 | 55篇 |
2000年 | 69篇 |
1999年 | 82篇 |
1998年 | 54篇 |
1997年 | 46篇 |
1996年 | 32篇 |
1995年 | 27篇 |
1994年 | 31篇 |
1993年 | 24篇 |
1992年 | 26篇 |
1991年 | 17篇 |
1990年 | 13篇 |
1989年 | 15篇 |
1987年 | 9篇 |
1986年 | 16篇 |
1985年 | 12篇 |
1983年 | 7篇 |
1982年 | 8篇 |
1978年 | 11篇 |
1977年 | 7篇 |
1976年 | 11篇 |
1975年 | 9篇 |
1974年 | 10篇 |
1972年 | 10篇 |
1971年 | 12篇 |
1970年 | 9篇 |
1968年 | 9篇 |
1967年 | 7篇 |
排序方式: 共有5179条查询结果,搜索用时 15 毫秒
121.
Herkel J Jagemann B Wiegard C Lazaro JF Lueth S Kanzler S Blessing M Schmitt E Lohse AW 《Hepatology (Baltimore, Md.)》2003,37(5):1079-1085
The ability to activate CD4 T cells is restricted to antigen-presenting cells that express major histocompatibility complex (MHC) class II molecules. Parenchymal cells normally do not express MHC class II molecules; however, in clinical hepatitis, viral or autoimmune, hepatocytes often exhibit aberrant MHC class II expression. It is not known whether MHC class II-expressing hepatocytes can function as antigen-presenting cells, but it has been suggested that aberrant MHC class II expression by parenchymal cells may cause autoimmune disease. Therefore, we generated transgenic mice that specifically overexpress class II transactivator molecules in hepatocytes. Hepatocytes from these mice exhibited stable MHC class II expression and were used to stimulate CD4 T cells from T-cell receptor transgenic mice and CD4 T-cell lines. MHC II-expressing hepatocytes featured costimulatory CD80 molecules and could serve as antigen-presenting cells that were able to process protein antigen and to activate specific CD4 T cells. Nevertheless, the transgenic mice with aberrant hepatocellular MHC class II expression did not exhibit any symptoms of autoimmune disease. In conclusion, MHC II-expressing hepatocytes, as found in clinical hepatitis, can present antigen and activate CD4 T cells. The ability of hepatocytes to present antigen on MHC II molecules does not seem to be a sufficient cause for inflammatory autoimmunity and hepatitis. However, we still need to explore whether such antigen presentation is occurring in vivo. The transgenic mice described in this study may serve as a model to study the immune interaction of hepatocytes and CD4 T cells in both in vitro and in vivo. 相似文献
122.
Pani MA Seidl C Bieda K Seissler J Krause M Seifried E Usadel KH Badenhoop K 《Clinical endocrinology》2002,56(6):773-777
OBJECTIVE: Addison's disease is associated with particular haplotypes of the human leucocyte antigen (HLA) region [DQA1*0501-DQB1*0201 (DQ2) and DQA1*0301-DQB1*0302 (DQ8)]. This locus harbours several human endogenous retroviral (HERV) long-terminal repeats (LTR). LTRs within the HLA region have been shown to confer additional susceptibility to type 1 diabetes and rheumatoid arthritis. DESIGN: We investigated the role of LTR3 and LTR13, both of which are located adjacent to the DQB1 gene, in Addison's disease. PATIENTS: Eighty-seven patients and 160 controls were genotyped for HLA-DQA, -DQB, and the presence or absence of LTR3 and LTR13. RESULTS: Significantly more patients' HLA alleles than those of controls carried the LTR13 insertion (19.0% vs. 10.6%, P = 0.0143), whereas there was only a trend for LTR3 (allele-wise chi-squared test: P = 0.0941). Both, LTR3 and LTR13 are in strong linkage disequilibrium with DQ8, which itself was significantly more frequent in patients than in controls (29.9% vs. 15.0%, P = 0.0089). However, significantly more alleles of DQ8+ patients than of DQ8+ controls carried the LTR13 insertion (44.2% vs. 18.8%, P = 0.0119), whereas we did not observe any difference for LTR3 in the DQ8+ subset (30.5 vs. 23.1%, P = 0.9416). CONCLUSIONS: We have found preliminary evidence that the endogenous retroviral element DQ-LTR13, but not LTR3, is associated with Addison's disease. LTR13 appears to enhance HLA-DQ8 mediated disease risk. This retroviral insertion therefore might represent a novel susceptibility factor in Addison's disease, but these findings need to be confirmed in a larger data set. 相似文献
123.
Gabriela Senti Bettina M. Prinz Vavricka Iris Erdmann Mella I. Diaz Richard Markus Stephen J. McCormack John J. Simard Brunello Wüthrich Reto Crameri Nicole Graf P?l Johansen Thomas M. Kündig 《Proceedings of the National Academy of Sciences of the United States of America》2008,105(46):17908-17912
The only causative treatment for IgE-mediated allergies is allergen-specific immunotherapy. However, fewer than 5% of allergy patients receive immunotherapy because of its long duration and risk of allergic side effects. We aimed at enhancing s.c. immunotherapy by direct administration of allergen into s.c. lymph nodes. The objective was to evaluate safety and efficacy compared with conventional s.c. immunotherapy. In a monocentric open-label trial, 165 patients with grass pollen-induced rhinoconjunctivitis were randomized to receive either 54 s.c. injections with pollen extract over 3 years [cumulative allergen dose 4,031,540 standardized quality units (SQ-U)] or 3 intralymphatic injections over 2 months (cumulative allergen dose 3,000 SQ-U). Patients were evaluated after 4 months, 1 year, and 3 years by nasal provocation, skin prick testing, IgE measurements, and symptom scores. Three low-dose intralymphatic allergen administrations increased tolerance to nasal provocation with pollen already within 4 months (P < 0.001). Tolerance was long lasting and equivalent to that achievable after standard s.c. immunotherapy (P = 0.291 after 3 years). Intralymphatic immunotherapy ameliorated hay fever symptoms (P < 0.001), reduced skin prick test reactivity (P < 0.001), decreased specific serum IgE (P < 0.001), caused fewer adverse events than s.c. immunotherapy (P = 0.001), enhanced compliance (P < 0.001), and was less painful than venous puncture (P = 0.018). In conclusion, intralymphatic allergen administration enhanced safety and efficacy of immunotherapy and reduced treatment time from 3 years to 8 weeks. 相似文献
124.
Oliver Ristow Carlos Gerngroß Markus Schwaiger Bettina Hohlweg-Majert Melanie Ristow Steffen Koerdt Roswitha Schuster Sven Otto Christoph Pautke 《Journal of cancer research and clinical oncology》2014,140(3):487-493
Purpose
To find out whether the most popular pathogenesis hypothesis of the bisphosphonate (BP) related osteonecrosis of the jaw (BRONJ) is comprehensible: (1) is there a higher bone remodeling in the jaw compared with other skeletal sites? (2) Is the bone turnover (BT) of the jaw overly altered after BP intake? (3) Are there gender- or entity-specific differences in BT before and after BP intake?Methods
Bone scintigraphies of 42 patients with prostate cancer were retrospectively analyzed (n = 21 with BP intake; n = 21 no BP). All patients received bone scintigraphy prior to the therapy and in the course of the treatment (after 12 and 24 months). Data were quantitatively analyzed using six predetermined regions of interest and compared with a breast cancer cohort.Results
The mandible revealed a similar BT as the femur and a significant lower BT compared with the maxilla. All investigated bone regions showed no significant changes under BP administration. Inter-gender differences revealed significantly lower BT values for the prostate cancer compared with the female breast cancer cohort, changes over the course of time could not be found.Conclusions
The finding that the mandible revealed a significant lower BT than the maxilla and the fact that 2/3 of the BRONJ cases occur in the mandible are inconsistent with the investigated hypothesis. Furthermore, the BT in the jawbone is not overly suppressed by BP. Thus, it seems implausible that a high BT and its over-suppression play the key role in the pathomechanism of BRONJ. 相似文献125.
126.
127.
128.
Tiziano Barbui Jürgen Thiele Heinz Gisslinger Guido Finazzi Alessandra Carobbio Elisa Rumi Maria Luigia Randi Irene Betozzi Alessandro M. Vannucchi Lisa Pieri Valentina Carrai Bettina Gisslinger Leonhard Müllauer Marco Ruggeri Alessandro Rambaldi Ayalew Tefferi 《American journal of hematology》2014,89(1):52-54
We examined the baseline features and clinical outcomes of 140 patients presenting with JAK2V617F positivity and a bone marrow morphology conforming with WHO criteria of polycythemia vera (PV), but a hemoglobin level of <18.5 g/dL in males (range 16.0–18.4) and <16.5 g/dL in females (range 15.0–16.4). This cohort operationally referred to as masked PV (mPV) was compared with 257 patients with overt PV and displayed male predominance, a more frequent history of arterial thrombosis and thrombocytosis. Incidence of thrombosis was similar between the two groups but mPV displayed significantly higher rates of progression to myelofibrosis and acute leukemia and inferior survival. In multivariable analysis mPV diagnosis was an independent predictor of poor survival along with age >65 years and leukocyte count >10 × 109/L. Our data suggest that mPV is a heterogeneous myeloproliferative neoplasia and not necessarily an early/ pre‐polycythemic form of classical PV that at onset in a small fraction of patients clinically may mimic essential thrombocythemia. On the other hand, the majority mPV may have a longer prodrome of undiagnosed PV or a disease biology akin to primary myelofibrosis‐post PV myelofibrosis that could explain the worsening of outcome in comparison to overt/classical manifestations. Am. J. Hematol. 89:52–54, 2014. © 2013 Wiley Periodicals, Inc. 相似文献
129.
130.
Nina Rogenhofer Michael K. Bohlmann Petra Beuter-Winkler Wolfgang Würfel Andreas Rank Christian J. Thaler Bettina Toth 《Annals of hematology》2014,93(3):385-392
Antithrombin (AT) deficiency is a rare hereditary thrombophilia with a mean prevalence of 0.02 % in the general population, associated with a more than ten-fold increased risk of venous thromboembolism (VTE). Within this multicenter retrospective clinical analysis, female patients with inherited AT deficiency were evaluated concerning the type of inheritance and extent of AT deficiency, medical treatment during pregnancy and postpartally, VTE risk as well as maternal and neonatal outcome. Statistical analysis was performed with SPPS for Windows (19.0). A total of 18 pregnancies in 7 patients were evaluated, including 11 healthy newborns ≥37th gestational weeks (gw), one small for gestational age premature infant (25th gw), two late-pregnancy losses (21st and 28th gw) and four early miscarriages. Despite low molecular weight heparin (LMWH) administration, three VTE occurred during pregnancy and one postpartally. Several adverse pregnancy outcomes occurred including fetal and neonatal death, as well as severe maternal neurologic disorders occurred. Patients with substitution of AT during pregnancy in addition to LMWH showed the best maternal and neonatal outcome. Close monitoring with appropriate anticoagulant treatment including surveillance of AT levels might help to optimize maternal and fetal outcome in patients with hereditary AT deficiency. 相似文献